Cel The main objective of the CellUp business innovation project is to develop and commercialize the new disruptive in-lineanalytics sensor for upstream cell culture process that the biopharmaceutical industry needs for the quality and processcontrol during the phases of process development, scale-up and manufacturing of vaccines and antibodies for humanmedicines based on eukaryote cells culture.This new bioprocess analyser will be the first industrial sensor able to perform in-line quantification of the main nutrients andmetabolites during the mammalian cell culture inside the bioreactor.Today, cell cultures in bioreactors are only monitored in real time with temperature, PH and Oxygen density sensors. Thenegative consequences of such a limited control are huge in terms of batch failures, time consumed at each scale-up phaseand in terms of untapped production yield improvement.Our company, with its unique integrated SWIFTS technology has the opportunity to fix the above described problem byoffering a high performance miniaturized in-line Raman analyzer which can be implemented as an industrial GMP sensor.Based on the needs expressed by several major industrial actors, the company has already developed a first productsuccessfully evaluated and released end of 2016 under the name ProCellics.The objective of the CellUp project is to go a step further in the integration of the Raman analyser thanks to a newconfiguration of our technology, called SWITS-CD. We will also develop a new “standard addition method” technology and arelated software to provide an easy and robust way to implement the monitoring of the cell culture. The key to the success ofthis new methodology development is a cell culture activity carried internally by our company.The total accessible market is estimated at 750 M€ for a first equipment of the 20,000 biopharma industry bioreactors, allowing the emergence of a European leader with more than 300 job creation over 10 years. Dziedzina nauki natural sciencescomputer and information sciencessoftwareengineering and technologyenvironmental biotechnologybioremediationbioreactorssocial sciencessociologyindustrial relationsautomationengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsnatural sciencesphysical sciencesopticsspectroscopy Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Zaproszenie do składania wniosków H2020-SMEInst-2016-2017 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-2-2016-2017 System finansowania SME-2 - SME instrument phase 2 Koordynator RESOLUTION SPECTRA SYSTEMS Wkład UE netto € 1 969 553,75 Adres 13 CHEMIN DU VIEUX CHENE 38240 MEYLAN Francja Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Auvergne-Rhône-Alpes Rhône-Alpes Isère Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 1 969 553,75
